1 The analgesic activity of CP-101,606, an NR2B subunit-selective N-methyl-D-aspartate (NMDA) receptor antagonist, was examined in carrageenan-induced hyperalgesia, capsaicin-and 4b-phorbol-12-myristate-13-acetate (PMA)-induced nociceptive tests in the rat. 2 CP-101,606 30 mg kg 71 , s.c., at 0.5 and 2.5 h after carrageenan challenge suppressed mechanical hyperalgesia without any apparant alternations in motor coordination or behaviour in the rat. 3 CP-101,606 also inhibited capsaicin-and PMA-induced nociceptive responses (licking behaviour) with ED 50 values of 7.5 and 5.7 mg kg 71 , s.c., respectively. 4 These results suggest that inhibition of the NR2B subunit of the NMDA receptor is eective in vivo at modulating nociception and hyperalgesia responses without causing the behavioural side eects often observed with currently available NMDA receptor antagonists.
Introduction
Accumulating evidence suggests that the N-methyl-D-aspartate (NMDA)-type glutamate receptors play a pivotal role in the transmission of excitatory signals from primary sensory neurones to the brain through the spinal cord (Dickenson, 1990) . NMDA receptors mediate Ca 2+ in¯ux into neurones, and its receptor-gated channel activity is blocked by Mg 2+ in a voltagedependent manner. Subunits of the NMDA receptors are classi®ed into two gene families, i.e., NR1 and NR2. A variety of compounds have been designed as antagonists targeting these subunits of the NMDA receptor for the treatment of neurodegenerative disorders, as well as acute and/or chronic pain and hyperalgesia. CP-101,606 is derived from ifenprodil, a well known a 1 -adrenoceptor antagonist exhibiting NMDA receptor antagonist activity via interaction with the polyamine modulatatory site (Carter et al., 1990) . CP-101,606 is an antagonist selective for the NR2B subunit, providing a novel tool to study the function of the NR2B subunit of NMDA receptors in vitro (Menniti et al., 1997) . CP-101,606 exhibited potent neuroprotective activity in hippocampus neurones (Menniti et al., 1997) where the NR2B subunit is predominantly expressed (Ishii et al., 1993) . This compound does not interact with (+)-a-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid (AMPA) or kainate receptors in the central nervous system . In the present study, to gain insight into a potential role of the NR2B subunit of NMDA receptors in transmission and/ or modulation of pain signals in vivo, we have examined the analgesic activity of CP-101,606 in hyperalgesia and nociceptive tests and compared its eect with those of standard NMDA receptor antagonists, MK-801 and memantine.
Methods

Animals
Male 4-to 5-week old Sprague-Dawley rats (100 ± 200 g body weight) were purchased from SLC Japan. Rats were maintained on stock diet and water ad libitum in climate-controlled rooms with a 12 h-light/dark cycle until experiments.
Carrageenan-induced mechanical hyperalgesia
One hundred microlitres of 1.5% carrageenan suspension was injected into the plantar surface of the hind paw of rats. CP-101,606 was subcutaneously (s.c.) administered twice at 0.5 and 2.5 h after carrageenan injection. The nociceptive threshold of mechanical hyperalgesia in the hind paw was measured according to the Randall-Selitto method (Randall & Selitto, 1957) .
Capsaicin-induced licking test
The capsaicin-induced licking behaviour, as an index of nociceptive response, was determined according to the method of Sakurada et al. (1992) . At 0.5 h after s.c. administration of test compounds, 100 ml of capsaicin (0.08 mg ml 71 ) was intraplantarly (i.pl.) injected in the hind paw of rats. The duration of licking was observed for 5 min immediately after the capsaicin challenge.
PMA-induced licking test
4b-Phorbol-12-myristate-13-acetate (PMA) 1 mg was injected i.pl. into the hind paw of rats. PMA-induced nociceptive response lasted over 15 ± 45 min, much longer than that of capsaicin. Therefore, the number of paw-licking behaviours was counted for 6 s every 30 s from 15 to 45 min following PMA injection. CP-101,606 (1 ± 30 mg kg 71 , s.c.) or piroxicam (10 mg kg 71 , s.c.) was administered 0.5 h before and dexamethsone (3 mg kg 71 , s.c.) was administered 4 h before PMA injection.
Rota-rod test
Motor coordination of rats was examined on the basis of their ability to walk on a rotating rod turning at 7 r.p.m. (model 7750, Ugo Basile, Italy). Animals that were able to walk on the rod for 120 s were selected for subsequent use in the test. Each rat was tested twice and the longer duration was taken as its motor-coordination score. The eect of CP-101,606 on the rota-rod score was determined in the same manner (30 mg kg 71 , s.c. injection twice at 0.5 and 2.5 h) as in the carrageenan-induced hyperalgesia experiment. The eects of a single dose of CP-101,606 (30 ± 60 mg kg 71 ), MK-801 (0.1 mg kg 71 ) and memantine (60 mg kg 71 ) were determined 0.5 h after s.c. administration.
Measurement of drug level
CP-101,606 was administered at 10 mg kg 71 , s.c., and after 0.5 h the rats were killed under ether anaesthesia. The cerebral spinal¯uid (CSF) was collected with a 1 ml syringe with a 26G needle. The brain and spinal cord were immediately excised, weighed and homogenized in ice-cold H 2 O. The sample (40 ± 100 ml) was mixed with 1 ml of 100% acetonitrile. After centrifugation at 1,8006g for 10 min, CP-101,606 in the resulting supernatant was analysed by liquid chromatography-linked mass spectroscopy with a Sciex API-III mass spectrometer equipped with a Hewlett-Packard HP1090 HPLC system.
Calculation of ED 50 values
ED 50 values are doses required to inhibit the duration of licking or the licking scores by 50%. The ED 50 values were calculated by computer-assisted linear regression analysis based on dose-response curves.
Chemicals
Methane sulphonate salt of CP-101,606, (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol and piroxicam were synthesized at P®zer Central Research. (+)-MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenzyl[a,d]cyclohepten-5,10-imine hydrogen maleate), memantine and dexamethasone were purchased from Sigma (St. Louis, MO, U.S.A.). Test compounds were dissolved in 0.1% methyl cellulose-0.9% NaCl. Carrageenan was purchased from Zushikagaku Laboratory Inc. (Japan) and suspended in saline at ®nal concentrations as described below. Capsaicin and PMA from Sigma (St. Louis, MO, U.S.A.) were dissolved in 10% dimethyl sulphoxide-saline and 2.5% acetone/saline solution, respectively.
Statistical tests
Experimental data were analysed by one-way ANOVA and the statistical signi®cance was determined by post hoc tests.
Results
Eect of CP-101,606 on carrageenan-induced hyperalgesia
In control rats, carrageenan injection decreased the nociceptive threshold of mechanical hyperalgesia in a time-dependent fashion (Figure 1) . The observed thresholds were 73+11, 47+8, and 41+10 g at 2, 3 and 4 h after the carrageenan injection, respectively, and signi®cantly lower than the original value (127+7 g) observed before carrageenan injection. Since CP-101,606 has a short half-life in the rat (t 1/2 =20 min, unpublished data), the compound was administered at 0.5 and 2.5 h after the carrageenan injection, as indicated by arrows in Figure 1 . CP-101,606, at a dose of 10 mg kg 71 , s.c., inhibited the decrease of the nociceptive threshold (Figure 1) . At a dose of 30 mg kg 71 , s.c., CP-101,606 almost completely inhibited carrageenan-induced hyperalgesia (Figure 1 ).
Eects on capsaicin-induced nociceptive response
Injection of capsaicin (8 mg) in a hind paw of rats immediately led to licking behaviour. In the vehicle group, the duration of licking behaviour was 49+7 s, n=5 (Figure 2a) . CP-101,606, MK-801 and memantine dose-dependently reduced the licking behaviour with ED 50 values of 7.5, 0.06 and 14.5 mg kg 71 , respectively (Figure 2a and b) .
Eects on PMA-induced nociceptive response
Like capsaicin, i.pl. injection of PMA (1 mg) into the hind paw of rats caused licking and¯inch behaviours, and the painassociated behaviours were observed for more than 50 min. In the vehicle group, the licking score was 18+3.3, n=5. Figure  2c shows that CP-101,606 signi®cantly reduced the score of licking behaviour (ED 50 value, 5.7 mg kg 71 , s.c.), suggesting antinociceptive activity of this compound against PMA-induced noxious stimulation. Importantly, piroxicam (10 mg kg 71 , s.c.), a cyclo-oxygenase inhibitor, and dexamethasone (3 mg kg 71 , s.c.) were inactive in this test (Figure 2d ).
Eects on motor coordination
CP-101,606 (30 mg kg 71 , s.c.) was administered at 0.5 and 2.5 h after carrageenan challenge, and its eect on motor coordination was examined by the rota-rod test (Figure 1) . CP-101,606 did not show any detectable eect on the rota-rod performance over the time period observed (up to 4 h). Likewise, no side eects were observed with a single administration of 606 up 
Discussion
Our present study demonstrates that CP-101,606 has anti-nociceptive activity in carrageenan-induced mechanical hyperalgesia (Figure 1) , and capsaicin and PMA-induced licking tests (Figure 2) . In all three tests, CP-101,606 did not produce any observable behavioural alterations such as ataxia, sedation, hyperactivity or circling behaviour over the time course of the experiments. Furthermore, CP-101,606 up to 60 mg kg 71 , s.c., did not cause any apparent CNS-related motor incoordination in the rota-rod test. Previously, Pagnozzi et al. also showed that CP-101,606 did not cause hyperactivity at doses up to 56 mg kg 71 , s.c., or 100 mg kg 71 , i.p. (Pagnozzi et al., 1995) . Although other NMDA receptor antagonists, such as MK-801 and memantine, exhibit potent analgesic activities, they are known to produce signi®cant behavioural alterations in animals. We con®rmed that MK-801 and memantine signi®cantly reduced capsaicin-induced duration of licking at 0.1 and 30 mg kg 71 , s.c., respectively. However, in the rota-rod test, 0.1 mg kg 71 of MK-801 or 60 mg kg 71 of memantine caused motor incoordination (data not shown).
CP-101,606 was derived from ifenprodil, a compound that exhibited NMDA receptor antagonist activity. Interaction of ifenprodil with the NMDA receptor is selective to the NR2B subunit (Williams et al., 1993; Williams, 1995) . However, compared to ifenprodil, CP-101,606 possesses greatly improved selectivity toward the NR2B subunit of the NMDA receptor . [ 3 H]-CP-101,606 binding site was found to be most dense in the hippocampus and cortex , and in situ hybridization revealed that NR2B subunit mRNA was expressed at high levels in these areas (Ishii et al., 1993) . Menniti et al. have recently demonstrated that glutamate-induced cell death of primary culture of rat hippocampal neurones was dose-dependently inhibited by CP-101,606 with an IC 50 value of 11 nM. Taken together, it is strongly suggested that CP-101,606 is an NR2B-selective antagonist. Drug concentrations of CP-101,606 0.5 h after s.c. administration at 10 mg kg 71 in the brain and the spinal cord tissues were 1,680+125 ng g 71 and 2,060+159 ng g
71
, respectively. Thus, CP-101,606 distributed in the brain and spinal cord at relatively high levels. Therefore, the analgesic activity of CP-101,606 shown in the present study is suggested to be evoked via blockade of NR2B subunit of NMDA receptor within the CNS.
In summary, CP-101,606, the NR2B subunit-selective NMDA receptor antagonist, has potent analgesic activity in rat hyperalgesia and nociceptive tests at doses causing no behavioural abnormality. The NR2B subunit of the NMDA receptor is considered to be a potential molecular target for the discovery of novel analgesics. 
